Jaleh Fallah

1.2k total citations · 1 hit paper
26 papers, 603 citations indexed

About

Jaleh Fallah is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jaleh Fallah has authored 26 papers receiving a total of 603 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Jaleh Fallah's work include Cancer Genomics and Diagnostics (6 papers), Prostate Cancer Treatment and Research (6 papers) and Renal cell carcinoma treatment (5 papers). Jaleh Fallah is often cited by papers focused on Cancer Genomics and Diagnostics (6 papers), Prostate Cancer Treatment and Research (6 papers) and Renal cell carcinoma treatment (5 papers). Jaleh Fallah collaborates with scholars based in United States, France and India. Jaleh Fallah's co-authors include Brian I. Rini, Adam J. Olszewski, Jorge J. Castillo, Daniel L. Suzman, Sundeep Agrawal, Laleh Amiri‐Kordestani, Richard Pazdur, Paul G. Kluetz, Shenghui Tang and Ronan Flippot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jaleh Fallah

23 papers receiving 596 citations

Hit Papers

FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxet... 2022 2026 2023 2024 2022 40 80 120
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
    2022 127 citations Jaleh Fallah, Sundeep Agrawal et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jaleh Fallah United States 10 224 211 204 204 94 26 603
Budhi Singh Yadav India 13 272 1.2× 240 1.1× 133 0.7× 146 0.7× 89 0.9× 85 666
Olga Martínez‐Sáez Spain 11 298 1.3× 458 2.2× 293 1.4× 343 1.7× 95 1.0× 60 832
Fabian Mairinger Germany 20 260 1.2× 393 1.9× 399 2.0× 361 1.8× 49 0.5× 81 1.0k
Jun Sakakibara‐Konishi Japan 15 148 0.7× 333 1.6× 368 1.8× 249 1.2× 62 0.7× 74 745
Elena Geuna Italy 16 130 0.6× 367 1.7× 242 1.2× 224 1.1× 34 0.4× 44 729
Mélissa Taylor France 18 340 1.5× 370 1.8× 317 1.6× 275 1.3× 49 0.5× 42 954
Matteo Clavarezza Italy 13 158 0.7× 405 1.9× 111 0.5× 135 0.7× 119 1.3× 46 629
Keun‐Yong Eom South Korea 18 137 0.6× 212 1.0× 130 0.6× 280 1.4× 112 1.2× 76 754
Pietro De Placido Italy 13 225 1.0× 488 2.3× 245 1.2× 396 1.9× 41 0.4× 53 816
Zhen Zheng China 15 285 1.3× 103 0.5× 292 1.4× 192 0.9× 40 0.4× 41 682

Countries citing papers authored by Jaleh Fallah

Since Specialization
Citations

This map shows the geographic impact of Jaleh Fallah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaleh Fallah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaleh Fallah more than expected).

Fields of papers citing papers by Jaleh Fallah

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaleh Fallah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaleh Fallah. The network helps show where Jaleh Fallah may publish in the future.

Co-authorship network of co-authors of Jaleh Fallah

This figure shows the co-authorship network connecting the top 25 collaborators of Jaleh Fallah. A scholar is included among the top collaborators of Jaleh Fallah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaleh Fallah. Jaleh Fallah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gani, Imran, et al.. (2025). Sevoflurane‐Associated Acute Liver Injury in Renal Transplantation and Review of Literature. Case Reports in Anesthesiology. 2025(1). 1303993–1303993.
2.
3.
4.
Fallah, Jaleh, Brian L. Heiss, Hee‐Koung Joeng, et al.. (2024). FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 30(22). 5003–5008. 9 indexed citations
5.
Fallah, Jaleh, Flora Mulkey, Mallorie H. Fiero, et al.. (2024). Equipoise Lost? Trial Conduct Challenges in an Era of Breakthrough Therapies. Journal of Clinical Oncology. 42(32). 3783–3787. 4 indexed citations
6.
Leapman, Michael, Jessica B. Long, Preston Sprenkle, et al.. (2024). Temporal and regional patterns of prostate cancer positron emission tomography imaging among commercial insurance beneficiaries in the United States.. Journal of Clinical Oncology. 42(4_suppl). 34–34. 1 indexed citations
7.
Fallah, Jaleh, Haley Gittleman, Chana Weinstock, et al.. (2024). Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis. JNCI Journal of the National Cancer Institute. 116(7). 1043–1050. 4 indexed citations
8.
Lee, Daniel, Haley Gittleman, Chana Weinstock, et al.. (2023). A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma. European Urology. 84(4). 373–378. 8 indexed citations
9.
Fallah, Jaleh, Sundeep Agrawal, Haley Gittleman, et al.. (2022). FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 29(9). 1651–1657. 127 indexed citations breakdown →
10.
Fallah, Jaleh, Haley Gittleman, Chana Weinstock, et al.. (2021). Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.. Journal of Clinical Oncology. 39(15_suppl). 4516–4516. 3 indexed citations
11.
Fallah, Jaleh, C. Marcela Díaz‐Montero, Patricia Rayman, et al.. (2020). Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. Clinical Genitourinary Cancer. 18(6). 500–508. 8 indexed citations
12.
Fallah, Jaleh, Ruby Gupta, Hong Li, et al.. (2020). Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. Targeted Oncology. 15(4). 477–483. 5 indexed citations
13.
Fallah, Jaleh, Rekha Chaudhary, Lisa R. Rogers, et al.. (2020). Clinical outcomes of the combination of bevacizumab and ttfields in patients with recurrent glioblastoma: Results of a phase II clinical trial.. Journal of Clinical Oncology. 38(15_suppl). 2537–2537. 14 indexed citations
14.
Fallah, Jaleh & Adam J. Olszewski. (2019). Diagnostic and therapeutic splenectomy for splenic lymphomas: analysis of the National Cancer Data Base. Hematology. 24(1). 378–386. 23 indexed citations
15.
Fallah, Jaleh & Brian I. Rini. (2019). HIF Inhibitors: Status of Current Clinical Development. Current Oncology Reports. 21(1). 6–6. 241 indexed citations
16.
Ahluwalia, Manmeet S., Harshil Dhruv, Jaleh Fallah, et al.. (2019). ACTR-43. GENOMIC ANALYSIS OF RESPONDERS OF PHASE II TRIAL OF TEMOZOLOMIDE AND TRC-102 (BASE EXCISION REPAIR INHIBITOR) IN BEVACIZUMAB-NAÏVE GLIOBLASTOMA AT FIRST RECURRENCE. Neuro-Oncology. 21(Supplement_6). vi23–vi23.
17.
Fallah, Jaleh, Lindor Qunaj, & Adam J. Olszewski. (2016). Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database. Blood Advances. 1(2). 112–121. 23 indexed citations
18.
Olszewski, Adam J., Jaleh Fallah, & Jorge J. Castillo. (2016). Human immunodeficiency virus‐associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base. Cancer. 122(17). 2689–2697. 38 indexed citations
19.
Olszewski, Adam J., Jaleh Fallah, Charles B. Eaton, Steven P. Treon, & Jorge J. Castillo. (2015). The Evolution of Management and Survival Outcomes of Waldenström Macroglobulinemia (WM) in the United States (US). Blood. 126(23). 882–882. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Budhi Singh Yadav Breakdown of academic impact, for papers by Olga Martínez‐Sáez Breakdown of academic impact, for papers by Fabian Mairinger Breakdown of academic impact, for papers by Jun Sakakibara‐Konishi Breakdown of academic impact, for papers by Elena Geuna Breakdown of academic impact, for papers by Mélissa Taylor Breakdown of academic impact, for papers by Matteo Clavarezza Breakdown of academic impact, for papers by Keun‐Yong Eom Breakdown of academic impact, for papers by Pietro De Placido Breakdown of academic impact, for papers by Zhen Zheng
Rankless by CCL
2026